Roflumilast in COPD: a Brazilian perspective

Roflumilast in COPD: a Brazilian perspective

Roberto Stirbulov,1 José R Jardim21Department of Respiratory Diseases, Santa Casa School of Medical Sciences in São Paulo, 2Department of Respiratory Diseases, Escola Paulista de Medicina, Federal University of São Paulo, Hospital São Pau...

Full description

Bibliographic Details
Main Authors:	Stirbulov R, Jardim JR
Format:	Article
Language:	English
Published:	Dove Medical Press 2015-09-01
Series:	International Journal of COPD
Online Access:	https://www.dovepress.com/roflumilast-in-copd-a-brazilian-perspective-peer-reviewed-article-COPD

Similar Items

The use of roflumilast in COPD: a review
by: Andrea Zanini, et al.
Published: (2015-08-01)

Vulnerable COPD patients with comorbidities: the role of roflumilast
by: Lipari M, et al.
Published: (2014-11-01)

Roflumilast: the fourth Mousquetaire in COPD pharmacological treatment
by: Bruno Balbi
Published: (2015-08-01)

Roflumilast: a review of its use in the treatment of COPD
by: Wedzicha JA, et al.
Published: (2016-01-01)

Does roflumilast induce phagocytic activity in COPD patients?
by: Ghosh B, et al.
Published: (2015-09-01)

Roflumilast: A Review of Chronic Obstructive Pulmonary Disease (COPD) Treatment
by: Ita Octafia, et al.
Published: (2021-01-01)

Roflumilast is effective in reducing COPD related exacerbations and improving CAT score
by: Biagio Polla
Published: (2015-08-01)

Adherence to roflumilast under dose-escalation strategy in Korean patients with COPD
by: Park TS, et al.
Published: (2019-04-01)

New therapeutic options in the management of COPD &ndash; focus on roflumilast
by: Sabina Antonela Antoniu
Published: (2011-02-01)

Roflumilast – a phosphodiesterase-4 inhibitor licensed for add-on therapy in severe COPD
by: Anne B Taegtmeyer, et al.
Published: (2012-07-01)

Roflumilast, a Novel Phosphodiesterase 4 Inhibitor, for COPD Patients with a History of Exacerbations
by: Stephen K. Field
Published: (2011-10-01)

Roflumilast, a Novel Phosphodiesterase 4 Inhibitor, for COPD Patients with a History of Exacerbations
by: Stephen K. Field
Published: (2011-01-01)

Potential treatment benefits and safety of roflumilast in COPD: a systematic review and meta-analysis
by: Yuan L, et al.
Published: (2016-06-01)

Glucocorticoid Receptor α Mediates Roflumilast’s Ability to Restore Dexamethasone Sensitivity in COPD
by: Reddy AT, et al.
Published: (2020-01-01)

Significant gas-exchange improvements reported after roflumilast in two cases of severe COPD
by: Bruno Sposato
Published: (2015-08-01)

Erratum for "Roflumilast, a Novel Phosphodiesterase 4 Inhibitor, for COPD Patients with a History of Exacerbations"
by: Stephen K. Field
Published: (2012-08-01)

Erratum for “Roflumilast, a Novel Phosphodiesterase 4 Inhibitor, for COPD Patients with a History of Exacerbations”
by: Stephen K. Field
Published: (2012-01-01)

Roflumilast, a phosphodiesterase-4 inhibitor, induces phagocytic activity in Greek COPD patients
by: Porpodis K, et al.
Published: (2015-06-01)

Reduction of exacerbations by the PDE4 inhibitor roflumilast - the importance of defining different subsets of patients with COPD
by: Goehring Udo M, et al.
Published: (2011-01-01)

Cost-effectiveness of roflumilast in combination with bronchodilator therapies in patients with severe and very severe COPD in Switzerland
by: Samyshkin Y, et al.
Published: (2013-01-01)

A case report of roflumilast in an elderly COPD patient: improving exercise capacity to improve quality of life
by: Daniela Parola, et al.
Published: (2015-08-01)

Does roflumilast decrease exacerbations in severe COPD patients not controlled by inhaled combination therapy? the REACT study protocol
by: Calverley PM, et al.
Published: (2012-06-01)

Refractory erythema annulare centrifugum treated with roflumilast
by: Pamela Calderon, BS, et al.
Published: (2024-05-01)

Roflumilast: Review of Phosphodiesterase-4 Inhibitor as Asthma Therapy
by: Rafina Syfridiana, et al.
Published: (2021-08-01)

Roflumilast attenuates allergen-induced inflammation in mild asthmatic subjects
by: Deschesnes Francine, et al.
Published: (2011-10-01)

Roflumilast Suppresses Adipogenic Differentiation via AMPK Mediated Pathway
by: Wan Xu, et al.
Published: (2021-06-01)

[Translated aticle] Topical and Oral Roflumilast in Dermatology: A Narrative Review
by: M. Mansilla-Polo, et al.
Published: (2024-03-01)

Roflumilast succeeds where traditional therapy fails: a case report
by: Gabriella Guarnieri
Published: (2015-08-01)

A NEW VALIDATED METHOD FOR DETERMINATION OF ROFLUMILAST IN TABLET BY CZE-UV
by: Tufan Güray

Roflumilast tópico y oral en dermatología. Una revisión narrativa
by: M. Mansilla-Polo, et al.
Published: (2024-03-01)

Prostaglandin E2 (PGE2) and Roflumilast Involvement in IPF Progression
by: Noa Moshkovitz, et al.
Published: (2023-08-01)

Effect of roflumilast on inflammatory cells in the lungs of cigarette smoke-exposed mice
by: De Cunto Giovanna, et al.
Published: (2008-08-01)

Cost-effectiveness of roflumilast as an add-on to triple inhaled therapy versus triple inhaled therapy in patients with severe and very severe COPD associated with chronic bronchitis in the UK
by: Kiff C, et al.
Published: (2018-09-01)

Roflumilast Prevents the Metabolic Effects of Bleomycin-Induced Fibrosis in a Murine Model.
by: Javier Milara, et al.
Published: (2015-01-01)

Longstanding tracheobronchomalacia: A forgotten cause of severe cough and its response to roflumilast
by: Veronica Ann Varney, et al.
Published: (2020-01-01)

Pre-Clinical Assessment of Roflumilast Therapy in a Thoracic Model of Spinal Cord Injury
by: Carla S. Sousa, et al.
Published: (2023-05-01)

Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β2-agonist fixed-dose combination: RE2SPOND rationale and study design
by: Rennard SI, et al.
Published: (2016-08-01)

Management of scrotal pruritus with topical roflumilast 0.3% once daily treatment
by: Paul S. Yamauchi, MD, PhD
Published: (2024-05-01)

Characterization of Resveratrol, Oxyresveratrol, Piceatannol and Roflumilast as Modulators of Phosphodiesterase Activity. Study of Yeast Lifespan
by: Adrián Matencio, et al.
Published: (2020-08-01)

Effect of Roflumilast in airways disorders via dual inhibition of phosphodiesterase and Ca2+-channel
by: Faisal Imam, et al.
Published: (2020-06-01)